A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas - Regional Cancer Care Associates LLC

Clinical Trials

A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Pharmacyclics
Protocol Number
PCYC-1136-CA
Cancer Diagnosis
To Learn More Call
201-510-0910